Description of oral glucocorticoid prescriptions in general population;Description des prescriptions de corticothérapies orales en population générale

Revue de Medecine Interne

Volumn 32, Issue 10, 2011, Pages 594-599

  Fardet, L ^a,b   Petersen, I ^b   Nazareth, I ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Glucocorticoids; Population based study; Prescription; Prevalence

Indexed keywords

CORTICOSTEROID; PREDNISOLONE;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG INDICATION; FEMALE; FOLLOW UP; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION; PRESCRIPTION; SEX DIFFERENCE; SHORT COURSE THERAPY; TREATMENT DURATION; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADULT; AGE DISTRIBUTION; AGED; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; SEX DISTRIBUTION;

EID: 80053191373     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2011.02.022     Document Type: Article

References (20)

1. Walsh L.J., Wong C.A., Pringle M., Tattersfield A.E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study. BMJ 1996, 313:344-346.
2. Lis Y., Mann R.D. The VAMP Research multi-purpose database in the UK. J Clin Epidemiol 1995, 48:431-434.
3. British national formulary (site Internet). Consultable sur (accès le 20 décembre 2010). http://bnf.org/bnf/.
4. Chisholm J. The Read clinical classification. BMJ 1990, 300:1092.
5. Epic: THIN Data from EPIC: a guide for researchers. London: EPIC; 2007. Dernier accès: 20 septembre 2010.
6. Bourke A., Dattani H., Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004, 12:171-177.
7. Lewis J.D., Schinnar R., Bilker W.B., Wang X., Strom B.L. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007, 16:393-401.
8. Ruigómez A., Martín-Merino E., Rodríguez L.A. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf 2010, 19:579-585.
9. Lo Re V., Haynes K., Forde K.A., Localio A.R., Schinnar R., Lewis J.D. Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 2009, 18:807-814.
10. Meal A., Leonardi-Bee J., Smith C., Hubbard R., Bath-Hextall F. Validation of THIN data for non-melanoma skin cancer. Qual Prim Care 2008, 16:49-52.
11. Davé S., Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf 2009, 18:704-707.
12. van Staa T.P., Leufkens H.G., Abenhaim L., Begaud B., Zhang B., Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000, 93:105-111.
13. Mantel-Teeuwisse A.K., Klungel O.H., Verschuren W.M., Porsius A.J., de Boer A. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?. Br J Clin Pharmacol 2002, 53:379-385.
14. Mazzaglia G., Yurgin N., Boye K.S., Trifirò G., Cottrell S., Allen E., et al. Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4-year retrospective study from national primary care data. Pharmacol Res 2008, 57:358-363.
15. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoids prescriptions in UK over the last 20years. Rheumatology (Oxford) sous presse [doi:10.1093/rheumatology/ker017].
16. Langley T.E., Szatkowski L., Gibson J., Huang Y., McNeill A., Coleman T., et al. Validation of The Health Improvement Network (THIN) primary care database for monitoring prescriptions for smoking cessation medications. Pharmacoepidemiol Drug Saf 2010, 19:586-590.
17. Rait G., Walters K., Griffin M., Buszewicz M., Petersen I., Nazareth I. Recent trends in the incidence of recorded depression in primary care. Br J Psychiatry 2009, 195:520-524.
18. Chronic Obstructive Pulmonary Disease (COPD) clinical guideline (site Internet). Consultatble sur (accès 20 décembre 2010). http://www.nice.org.uk/article.asp?a=91784.
19. Fardet L., Hanslik T., Blanchon T., Perdoncini-Roux A., Kettaneh A., Tiev K.P., et al. Mesures adjuvantes à une corticothérapie systémique prolongée: description des pratiques des médecins internistes français. Rev Med Interne 2008, 29:975-980.
20. Fardet L., Blanchon T., Perdoncini-Roux A., Kettaneh A., Tiev K., Turbelin C., et al. Perception par les médecins internistes de la fréquence et de la gêne induite par les effets indésirables d'une corticothérapie systémique prolongée. Rev Med Interne 2009, 30:113-118.